Clinical Trial Update: Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers [Phase 2]

View source ↗

Summary

Phase II neoadjuvant immune checkpoint inhibitor trial in patients with resectable gastric, esophageal, or liver cancer; currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer
• Liver Cancer

Snippet

Sponsor: Asan Medical Center | Conditions: Subjects With Resectable and Localized Gastric Cancer, Subjects With Resectable Esophageal Cancer or Liver Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING